Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
BASECAMP-1: Leveraging human leukocyte antigen (HLA) loss of heterozygosity (LOH) in solid tumors by next-generation sequencing (NGS) to identify patients with relapsed solid tumor for future logic-gated Tmod CAR T-cell therapy Simeone, D. M., Hecht, J., Patel, S., Morelli, M., Kirtane, K., Borad, M. J., Maus, M., Sunwoo, J. B., Welling, T., Lin, Y., Garon, E. B., Kopetz, S., Locke, F. L., Liechty, K. B., Lozac'hmeur, A., Beutner, K., Ng, E., Go, W. Y., Maloney, D. G., Molina, J. R. LIPPINCOTT WILLIAMS & WILKINS. 2022
View details for Web of Science ID 000863680304843